OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Tolaney on the Evolution of Treatment in HER2+ Breast Cancer

October 1st 2020

Sara M. Tolaney, MD, MPH, discusses the evolution of treatment in HER2-positive breast cancer.

Dr. Hamilton on Initial Findings From the LIO-1 Trial in Advanced Metastatic Tumors

October 1st 2020

Erika P. Hamilton, MD, highlights initial findings from the ongoing phase 1b/2 LIO-1 trial in advanced metastatic tumors.

Dr. Zalcberg on the Management of Patients With GIST

October 1st 2020

John Zalcberg, PhD, OAM, discusses the management of patients with gastrointestinal stromal tumor.

Dr. Chu on the Role of Pembrolizumab in dMMR/MSI-H mCRC

October 1st 2020

Edward Chu, MD, MMS, discusses the role of pembrolizumab in patients with mismatch repair deficient or microsatellite instability–high metastatic colorectal cancer.

Dr. Pal on the Safety Profile of Cabozantinib/Atezolizumab in Advanced RCC

October 1st 2020

Sumanta K. Pal, MD, discusses the safety profile of cabozantinib in combination with atezolizumab in advanced renal cell carcinoma.

Dr. Giaccone on Treatment Options in NSCLC

October 1st 2020

Giuseppe Giaccone, MD, PhD, discusses current treatment options in non–small cell lung cancer.

Dr. Goy on the Utility of NGS in Identifying Aggressive MCL Subtypes

October 1st 2020

Andre Goy, MD, MS, discusses the utility of next-generation sequencing in identifying aggressive subtypes of mantle cell lymphoma.

Dr. Kantoff on Approaches for Progressive Prostate Cancer Following Androgen Blockade

October 1st 2020

Philip W. Kantoff, MD, discusses current approaches for patients with metastatic hormone-sensitive prostate cancer, and nonmetastatic/metastatic castration-resistant prostate cancer who progress on androgen blocking agents.

Dr. Sam on the Importance of Performing Geriatric Assessments During the COVID-19 Pandemic

September 30th 2020

Christine Sam, MD, discusses the importance of performing geriatric assessments during the coronavirus disease 2019 pandemic.

Dr. Nixon on the Role of IHC and Multiplex PCR in Detecting MSI-H Tumors

September 30th 2020

Andrew B. Nixon, PhD, MBA, discusses the role of immunohistochemistry and multiplex polymerase chain reactions tests in detecting microsatellite instability–high tumors.

Dr. Kristeleit on QoL With Dostarlimab in dMMR/MSI-H Endometrial Cancer

September 30th 2020

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the importance of patient-reported outcomes in the phase 1 GARNET trial in advanced or recurrent mismatch repair deficient/microsatelite instability-high endometrial cancer.

Dr. Reck on the Safety of Pembrolizumab in KEYNOTE-024 in Metastatic NSCLC

September 30th 2020

Martin Reck, MD, PhD, discusses the safety profile observed with of pembrolizumab versus chemotherapy in patients with metastatic non–small cell lung cancer in the phase 3 KEYNOTE-024 trial.

Dr. McDermott on Rationale for Darolutamide Plus ADT/Radiation in High-Risk Prostate Cancer

September 30th 2020

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the rationale for the addition of darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk prostate cancer.

Dr. Glitza Olivia on the Potential Utility of Pembrolizumab/Selinexor in Advanced Melanoma

September 30th 2020

Isabella C. Glitza Oliva, MD, PhD, MS, discusses the potential utility of pembrolizumab in combination with selinexor in advanced melanoma.

Dr. Eggermont on the Rationale for Evaluating Adjuvant Pembrolizumab in Advanced Melanoma

September 30th 2020

Alexander M. M. Eggermont, MD, PhD, discusses the rationale for the phase 3 EORTC 1325/KEYNOTE-054 trial, evaluating adjuvant pembrolizumab versus placebo, in advanced melanoma.

Dr. Shah on the Rationale for the KEYNOTE-590 Trial in Esophageal Carcinoma

September 30th 2020

Manish A. Shah, MD, discusses the rationale for the phase 3 KEYNOTE-590 trial in locally advanced or metastatic esophageal carcinoma.

Dr. Nguyen on Treatment Considerations in High-Risk Prostate Cancer

September 29th 2020

Paul L. Nguyen, MD, discusses treatment considerations in high-risk prostate cancer.

Dr. Choudhury on the Designs of Key Trials in Nonmetastatic CRPC

September 29th 2020

Atish D. Choudhury, MD, PhD, discusses the design of key clinical trials in nonmetastatic castration-resistant prostate cancer.

Dr. Hussain on the Rationale to Target the DNA Repair Pathway in mCRPC

September 29th 2020

Maha Hussain, MD, FACP, FASCO, discusses the rationale for targeting the DNA repair pathway in metastatic castration-resistant prostate cancer.

Dr. Pagel on Determining Treatment Based on Genetic Risk in Double- and Triple-Hit Lymphoma

September 29th 2020

John M. Pagel, MD, PhD, discusses the utility of rituximab with etoposide, doxorubicin, cyclophosphamide, vincristine, and prednisone in double- and triple-hit lymphoma.